Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 13/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | CSGALNACT1 | Q8TDX6 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935861 | 1.00 | MME (0.59) | MMEACECSGALNACT1MEN1ALDH1A1 | |
| SCHEMBL9935443 | 0.95 | MME (0.57) | MMEACECSGALNACT1MEN1ALDH1A1 | |
| SCHEMBL9935440 | 0.95 | MME (0.57) | MMEACECSGALNACT1MEN1ALDH1A1 | |
| SCHEMBL9936016 | 0.91 | MME (0.60) | MMEACECSGALNACT1MEN1KMT2A | |
| SCHEMBL9936010 | 0.91 | MME (0.60) | MMEACECSGALNACT1MEN1KMT2A | |
| SCHEMBL9935602 | 0.89 | MME (0.59) | MMEACECSGALNACT1MEN1KMT2A | |
| SCHEMBL9934668 | 0.89 | MME (0.58) | MMEACECSGALNACT1MEN1KMT2A | |
| SCHEMBL9934673 | 0.89 | MME (0.58) | MMEACECSGALNACT1MEN1KMT2A | |
| SCHEMBL9935607 | 0.89 | MME (0.59) | MMEACECSGALNACT1MEN1KMT2A | |
| SCHEMBL9934387 | 0.88 | MME (0.65) | MMEACECSGALNACT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-9120758-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2651900-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885CSGALNACT1 1670/4885 |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885CSGALNACT1 1670/4885 |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885CSGALNACT1 1670/4885 |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885CSGALNACT1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.